PT - JOURNAL ARTICLE AU - Uyoga, Sophie AU - M.O. Adetifa, Ifedayo AU - Karanja, Henry K. AU - Nyagwange, James AU - Tuju, James AU - Wanjiku, Perpetual AU - Aman, Rashid AU - Mwangangi, Mercy AU - Amoth, Patrick AU - Kasera, Kadondi AU - Ng’ang’a, Wangari AU - Rombo, Charles AU - Yegon, Christine AU - Kithi, Khamisi AU - Odhiambo, Elizabeth AU - Rotich, Thomas AU - Orgut, Irene AU - Kihara, Sammy AU - Otiende, Mark AU - Bottomley, Christian AU - N. Mupe, Zonia AU - W. Kagucia, Eunice AU - E Gallagher, Katherine AU - Etyang, Anthony AU - Voller, Shirine AU - N. Gitonga, John AU - Mugo, Daisy AU - N. Agoti, Charles AU - Otieno, Edward AU - Ndwiga, Leonard AU - Lambe, Teresa AU - Wright, Daniel AU - Barasa, Edwine AU - Tsofa, Benjamin AU - Bejon, Philip AU - I. Ochola-Oyier, Lynette AU - Agweyu, Ambrose AU - Scott, J. Anthony G. AU - Warimwe, George M. TI - Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors AID - 10.1101/2020.07.27.20162693 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.27.20162693 4099 - http://medrxiv.org/content/early/2020/07/29/2020.07.27.20162693.short 4100 - http://medrxiv.org/content/early/2020/07/29/2020.07.27.20162693.full AB - Background There are no data on SARS-CoV-2 seroprevalence in Africa though the COVID-19 epidemic curve and reported mortality differ from patterns seen elsewhere. We estimated the anti-SARS-CoV-2 antibody prevalence among blood donors in Kenya.Methods We measured anti-SARS-CoV-2 spike IgG prevalence by ELISA on residual blood donor samples obtained between April 30 and June 16, 2020. Assay sensitivity and specificity were 83% (95% CI 59-96%) and 99.0% (95% CI 98.1-99.5%), respectively. National seroprevalence was estimated using Bayesian multilevel regression and post-stratification to account for non-random sampling with respect to age, sex and region, adjusted for assay performance.Results Complete data were available for 3098 of 3174 donors, aged 15-64 years. By comparison with the Kenyan population, the sample over- represented males (82% versus 49%), adults aged 25-34 years (40% versus 27%) and residents of coastal Counties (49% versus 9%). Crude overall seroprevalence was 5.6% (174/3098). Population-weighted, test- adjusted national seroprevalence was 5.2% (95% CI 3.7– 7.1%). Seroprevalence was highest in the 3 largest urban Counties - Mombasa (9.3% [95% CI 6.4-13.2%)], Nairobi (8.5% [95% CI 4.9-13.5%]) and Kisumu (6.5% [95% CI 3.3-11.2%]).Conclusions We estimate that 1 in 20 adults in Kenya had SARS-CoV-2 antibodies during the study period. By the median date of our survey, only 2093 COVID-19 cases and 71 deaths had been reported through the national screening system. This contrasts, by several orders of magnitude, with the numbers of cases and deaths reported in parts of Europe and America when seroprevalence was similar.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded by the Wellcome Trust (220991/Z/20/Z; 203077/Z/16/Z). Sophie Uyoga is funded by DELTAS Africa Initiative [DEL-15-003], Isabella Ochola-Oyier is funded by a Wellcome Trust Intermediate Fellowship (107568/Z/15/Z), Ambrose Agweyu is funded by a DFID/MRC/NIHR/Wellcome Trust Joint Global Health Trials Award (MR/R006083/1), J. Anthony G Scott is funded by a Wellcome Trust Senior Research Fellowship (214320) and the NIHR Health Protection Research Unit in Immunisation, Ifedayo Adetifa is funded by an MRC/DFID African Research Leader Fellowship (MR/S005293/1) and by the NIHR-MPRU at UCL (grant 2268427 LSHTM). GMW is supported by a fellowship from the Oak Foundation. Charles N. Agoti is funded by the DELTAS Africa Initiative [DEL-15-003], and the Department for International Development and Wellcome (220985/Z/20/Z). The authors did not received payment or services from a third party.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Scientific and Ethics Review Unit (SERU) of the Kenya Medical Research Institute.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data and analysis scripts for this manuscript shall be made available at the KWTRP Harvard Dataverse: (https://dataverse.harvard.edu/dataverse/kwtrp). Some of the clinical dataset contains potentially identifying information on participants and is stored under restricted access. Requests for access to the restricted dataset should be made to the Data Governance Committee (dgc@kemri-wellcome.org) of the KEMRI-Wellcome Trust Research Programme.